Safety Study of Oral Sodium Phenylbutyrate in Subjects With ALS (Amyotrophic Lateral Sclerosis)

Completed · Phase 1/Phase 2

Conditions studied: Amyotrophic Lateral Sclerosis

In brief

The purpose of the study is to evaluate the safety of sodium phenylbutyrate (NaPB) treatment in subjects with amyotrophic lateral sclerosis (ALS) and the ability to take this medication without major side effects.

Key facts

Study ID

NCT00107770

Run by

US Department of Veterans Affairs

People needed

40

Starts

2005-04-01

Expected to finish

2007-09-01

Last updated by the study team

2010-01-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosed with ALS
• At least 18 years of age
• Women, who can become pregnant, must actively use effective birth control measures

You may not qualify if…

• Must not have any other neurological (nervous system) disease
• Veterans only are eligible to participate at VA sites.

Where it is running

• VA Medical Center, Iowa City — Iowa City, Iowa, United States
• VA Medical Center, Lexington — Lexington, Kentucky, United States
• VA Maryland Health Care System, Baltimore — Baltimore, Maryland, United States
• Edith Nourse Rogers Memorial Veterans Hospital, Bedford — Bedford, Massachusetts, United States
• VA Medical Center, Jamaica Plain Campus — Boston, Massachusetts, United States
• VA Medical Center, Syracuse — Syracuse, New York, United States
• VA Medical Center, Durham — Durham, North Carolina, United States
• VA Medical Center, Cincinnati — Cincinnati, Ohio, United States
• VA Pittsburgh Health Care System — Pittsburgh, Pennsylvania, United States
• Michael E. DeBakey VA Medical Center (152) — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.